News

March 28, 2018March 28, 2018

FDA Approves Cimzia Label Update Essential for Childbearing Women with Inflammatory Diseases

News

The U.S. Food and Drug Administration (FDA) recently approved UCB’s request for a label update for Cimzia (certolizumab pegol) indicating low transfer levels of the medication from mother to child through ... Read more

March 27, 2018March 27, 2018

An IBD Biologic Does Not Increase Woman’s Risk of Birth Problem, Study Finds

News

Women who take biologics for autoimmune disorders either three months before or during their pregnancy are not at higher risk of a preterm birth or having a smaller than normal ... Read more

March 26, 2018March 26, 2018

Investigational Therapy RHB-107 Holds Potential to Treat IBD, Other Disorders, RedHill Announces

News

RedHill Biopharma is evaluating the potential of its proprietary therapy RHB-107 (upamostat, formerly known as Mesupron) to treat inflammatory digestive diseases and cancer, the company announced in a press release. Results ... Read more

March 23, 2018March 23, 2018

Artificial Sweetener Splenda Found to Worsen Symptoms of Crohn’s Disease in New Mouse Study

News

The artificial sweetener Splenda (sucralose maltodextrin) was recently found to worsen gut inflammation in mice with Crohn’s disease, while no effects were seen in mice without the condition. The investigation, ... Read more

March 20, 2018March 20, 2018

Dietary Therapy in Children May Increase Risk of Eating Disorders, Study Suggests

News

Researchers have found that dietary therapy in children with chronic illnesses, such as inflammatory bowel disease (IBD), may increase their risk for unusual eating habits or eating disorders. The review ... Read more

March 19, 2018March 19, 2018

TNF Inhibitors Do Not Increase Risk of Tumor Malignancy in Pediatric IBD, Study Shows

News

Treatment of pediatric inflammatory bowel disease (pIBD) with tumor necrosis factor inhibitors (TNFi) does not increase the risk for malignancy, researchers report. The study with that finding, “Risk of malignancy associated ... Read more

March 16, 2018March 16, 2018

Protalix Alleviates Ulcerative Colitis, Sending Some Cases Into Remission, Phase 2 Trial Shows

News

Protalix BioTherapeutics’ OPRX-106 alleviated ulcerative colitis and in some cases sent it into remission, a Phase 2 clinical trial shows . OPRX-106 is a TNF inhibitor that Protalix scientists grew from ... Read more

March 13, 2018March 13, 2018

IBDHorizons Announces First Annual Midwest Meeting, Focusing on IBD Education

News

Nonprofit organization IBDHorizons recently announced its first annual Midwest meeting taking place March 24 in Columbus, Ohio. The inaugural event will focus on diagnosis, management, treatment, and advances in inflammatory bowel ... Read more

March 12, 2018March 12, 2018

FDA Advisory Panel Favors Extended Use of Xeljanz by Certain Ulcerative Colitis Patients

News

An advisory arm of the U.S. Food and Drug Administration (FDA) gave two positive recommendations to Pfizer’s supplemental New Drug Application, seeking FDA approval for extended use of Xeljanz (tofacitinib) by certain adult ... Read more

March 8, 2018

Heart Attack Risk Significantly Higher in Young Adult IBD Patients, Research Suggests

News

Young adults with inflammatory bowel disease (IBD) are at greater risk of having a heart attack. Because of that, IBD should be considered an independent risk factor for heart disease. ... Read more